In addition to the FDA-approved biomarkers, TMB and PD-L1 tumor proportion score (143, 145), TME-related immune gene signatures (141, 148), neutrophil-to-lymphocyte ratio (142, 143), and mutant allele tumor heterogeneity (MATH) (145) were reported as potential biomarkers predicting response to ICIs. This evidence concerns the gene CD274 and neoplasm.